论文部分内容阅读
目的探讨口服胺碘酮治疗心房纤颤的临床疗效及安全性。方法将32例心房纤颤患者随机分为治疗组(n=16)和对照组(n=16)。随访时间为12个月后,比较两组患者转复为窦性心律的时间、阵发性房颤的发作次数和时间。结果治疗12个月后,胺碘酮组显效率、有效率及窦性心律的维持率均明显高于对照组(P<0.05)。结论口服胺碘酮治疗心房纤颤具有良好的疗效且不良反应小,是相对安全有效的抗心律失常药。
Objective To investigate the clinical efficacy and safety of oral amiodarone in the treatment of atrial fibrillation. Methods 32 patients with atrial fibrillation were randomly divided into treatment group (n = 16) and control group (n = 16). The follow-up time was 12 months. The time of sinus rhythm and paroxysmal atrial fibrillation were compared between the two groups. Results After 12 months of treatment, the apparent efficiency, effective rate and the maintenance rate of sinus rhythm in amiodarone group were significantly higher than those in control group (P <0.05). Conclusions Oral amiodarone is a safe and effective antiarrhythmic drug in the treatment of atrial fibrillation with good efficacy and less adverse reactions.